Filters close
Newswise: Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets
Released: 4-Oct-2024 9:05 AM EDT
Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets
Dana-Farber Cancer Institute

Weighted blankets are available to patients receiving infusions at all Dana-Farber locations as the result of a project led by staff nurse Cheri Hermann, BSN, RN, OCN. The initiative dates to March 2020, when she observed heightened anxiety in patients whose loved ones were unable to accompany them to appointments during the COVID-19 pandemic.

Released: 26-Sep-2024 9:30 AM EDT
Dana-Farber Cancer Institute Leads the Launch of IGNITE Consortium to Eradicate Health Inequities in Pediatric Cancer Care
Dana-Farber Cancer Institute

In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology health equity research consortium. This groundbreaking initiative aims to eradicate inequities for children, adolescents, and young adults diagnosed with cancer or blood disorders via the rapid development and evaluation of policy-relevant, evidence-based and community informed health equity interventions.

Newswise: Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer
Released: 13-Sep-2024 11:05 AM EDT
Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer
Dana-Farber Cancer Institute

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer. Research led by Dana-Farber Cancer Institute.

Newswise: Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Released: 13-Sep-2024 10:05 AM EDT
Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Dana-Farber Cancer Institute

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma.

Newswise: Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024
9-Sep-2024 8:05 AM EDT
Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024
Dana-Farber Cancer Institute

Novel treatments, including targeted therapies and antibody drug conjugates, as well as research into improving quality of life for patients with breast cancer, headline studies led by Dana-Farber Cancer Institute and presented at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.

25-Jun-2024 12:05 PM EDT
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
Dana-Farber Cancer Institute

• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment • Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence

Newswise: Researchers report first effective use of immunotherapy for most common subtype of colorectal cancer
Released: 25-Jun-2024 1:05 PM EDT
Researchers report first effective use of immunotherapy for most common subtype of colorectal cancer
Dana-Farber Cancer Institute

These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.

Newswise: Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
18-Jun-2024 10:05 AM EDT
Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
Dana-Farber Cancer Institute

An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.

Newswise: New Guidelines for Radiation Therapy for HPV-Associated Head and Neck Cancer
Released: 18-Jun-2024 11:05 AM EDT
New Guidelines for Radiation Therapy for HPV-Associated Head and Neck Cancer
Dana-Farber Cancer Institute

New recommendations on the optimal use of radiation therapy for HPV-associated OPSCC are based on evidence from multiple clinical trials and aim to maintain good outcomes and reduce acute and late effects.

Newswise: Telehealth can significantly reduce greenhouse gas emissions associated with cancer care, study finds
Released: 3-Jun-2024 9:05 AM EDT
Telehealth can significantly reduce greenhouse gas emissions associated with cancer care, study finds
Dana-Farber Cancer Institute

Based on an analysis of data from a regional cancer center, Dana-Farber Cancer Institute researchers calculate that, nationwide, cancer care that utilizes telehealth and local care would generate 33.1% less greenhouse gas emissions than the traditional model of in-person care. Study published in JAMA Oncology.

Released: 1-Jun-2024 8:05 AM EDT
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.

Newswise: Dana-Farber researchers uncover disparities in lived experiences for patients and physicians
29-May-2024 8:05 AM EDT
Dana-Farber researchers uncover disparities in lived experiences for patients and physicians
Dana-Farber Cancer Institute

Four teams of Dana-Farber Cancer Institute investigators have found that people experience discrimination and bias in different ways and in more realms of cancer care than previously understood. The findings, in different studies, suggest that oncology professionals and the systems they work in have more work to do to adapt to the realities of increasing diversity and inclusion, not only in the patient population but also in the oncology workforce.

Newswise: Most young women treated for breast cancer can have children, study shows
23-May-2024 1:05 PM EDT
Most young women treated for breast cancer can have children, study shows
Dana-Farber Cancer Institute

New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children.

Released: 6-May-2024 11:30 AM EDT
Dana-Farber review article examines past and guides future efforts to reduce cancer disparities
Dana-Farber Cancer Institute

Investigators at Dana-Farber Cancer Institute have examined the historical evolution of Community Outreach and Engagement initiatives at both the National Cancer Institute (NCI) and National Cancer Institute-Designated Cancer Centers (NCI-DCCs).

Newswise: Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
Released: 3-May-2024 12:00 PM EDT
Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
Dana-Farber Cancer Institute

Follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC. Research led by Dana-Farber Cancer Institute and others.

Released: 24-Apr-2024 9:00 AM EDT
Dana-Farber nurses present research and evidence-based studies at 2024 Oncology Nursing Society Congress
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute nurse scientists and clinicians are presenting key studies and projects at the 49th annual Oncology Nursing Society (ONS) Congress on April 24-28, 2024, in Washington, D.C.

Newswise: Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the Advancement of Science
Released: 18-Apr-2024 10:05 AM EDT
Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the Advancement of Science
Dana-Farber Cancer Institute

Kevin Haigis, PhD, Chief Scientific Officer, Dana-Farber Cancer Institute, has been named Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is a distinguished lifetime honor bestowed upon AAAS members by their peers.

Newswise: Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype
Released: 5-Apr-2024 3:50 PM EDT
Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype
Dana-Farber Cancer Institute

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.

Newswise: Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024
Released: 5-Apr-2024 3:05 PM EDT
Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024
Dana-Farber Cancer Institute

Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers.

Released: 28-Mar-2024 11:30 AM EDT
Private and Secure Generative AI Tool Supports Operations and Research at Dana-Farber
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has implemented an artificial intelligence (AI) application intended for general use in a medical center or hospital.



close
0.13762